
Conference Coverage
about 1 month ago
What Patients With Cancer Should Know About Radiation Side Effectsabout 1 month ago
Hernexeos Effective in HER2-Mutated NSCLCabout 1 month ago
Insights Into Advancing Care and Research in Hairy Cell Leukemiaabout 2 months ago
Buparlisib Plus Chemo Fails to Improve Head and Neck Cancer Survivalabout 2 months ago
VCN-01 with Standard Care Boosts Survival, Shows Safety in PDACabout 2 months ago
Camrelizumab Combo Extends Survival in Metastatic Cervical Cancerabout 2 months ago
Alecensa Improves 4-Year Survival in Early ALK-Positive Lung CancerLatest Content

Essential Insights on GIST and Gleevec for Patients

TARA-002 Shows Potential in BCG-Naive NMIBC Treatment

What Patients With AML Need to Know About Azacitidine and Venclexta

FDA Approves Breyanzi in Relapsed/Refractory Marginal Zone Lymphoma

11 Years Living With Stage 4 Cancer Inspires Gratitude and Reflection

Shorts






Podcasts
Videos
All News

Stage 1 myelofibrosis is a manageable early-stage blood cancer that requires ongoing monitoring and personalized care to support long-term health.

As part of her journey with stage 3 inflammatory breast cancer, Lindsey Gunter experienced chemotherapy side effects so severe that she was unable to walk.

I experienced acute myeloid leukemia twice. Had it not been for follow up appointments I would not be here.

This guide explains how squamous cell lung cancer is diagnosed and treated at each stage to help patients talk openly with their oncology team.

The U.S. commercial launch of LYMPHIR offers a new treatment option for patients with relapsed/refractory stage 1 to 3 cutaneous T-cell lymphoma.

Dr. Girindra Raval sat down for an interview with CURE to discuss what patients with EGFR-mutated lung cancer should know about their treatment options.

I share how my sister’s final days felt different from her many rebounds and how I continue to process the grief of losing her after years of anticipation.

Nona Baker, who was first diagnosed with a blood cancer in 1991, shares her experience with polycythemia vera.

In November 2025, the FDA issued multiple oncology approvals that expanded treatment access for patients with breast, lung, blood and solid tumor cancers.

The FDA granted traditional approval to Jaypirca for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr. Charles M. Rudin discussed recent treatment advancements for patients with small cell lung cancer.

IGV-001 improved survival for newly diagnosed glioblastoma in a phase 2b trial, with patients living a median 20.3 months and no serious safety issues.

I found purpose again after my myeloma diagnosis when I returned to teaching and shared my work, moments that reminded me I could still grow and reconnect.

I explain how the words caregiver and incurable shaped my wife’s cancer journey and why I believe more hopeful language better reflects our experience.

Cindy and Katie share how finding a friend who understood the caregiving journey made the experience less isolating and helped them navigate loss and hope.














